Quince Therapeutics, Inc.

Ownership Transactions Reported by 21 Insiders

Symbol
QNCX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
611 Gateway Blvd., Suite 273, South San Francisco, CA

Insiders trading volume in the past year

Quince Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
David Lamond Director $6M +$168K +2.88% Jun 5, 2024
Dirk Thye CEO AND CHIEF MEDICAL OFFICER, Director $591K +$107K +22.2% Aug 29, 2024
Philip S. Low Director $488K May 19, 2022
Christopher P. Lowe Interim CEO, COO & CFO $249K Mar 3, 2022
Brendan Hannah Chief Business Officer And Coo $187K +$24.2K +14.9% Aug 19, 2024
Leslie Holsinger EVP, Preclinical Development $139K Jun 6, 2022
Michael J. Detke Chief Medical Officer $132K Mar 3, 2022
Caryn Gordon McDowell Chief Legal & Adm. Officer $115K Jun 6, 2022
Charles S. Ryan President $79.6K +$31.5K +65.3% Aug 20, 2024
Luca Benatti Director $75.4K Jun 5, 2024
Ted Monohon Chief Accounting Officer & VP $25.8K Mar 6, 2023
Guenter Janhofer Chief Scientific Officer $14.1K Oct 23, 2023
Margaret McLoughlin Director $7.52K Jun 5, 2024
Stephen S. Dominy Chief Scientific Officer, Director Jan 3, 2022
Casey Lynch Chief Executive Officer, Director Jan 3, 2022
Marwan Sabbagh Director Mar 14, 2022
Karen L. Smith Chief Medical Officer Feb 1, 2023
Una S. Ryan Director Jun 5, 2024
Christopher J. Senner Director Jun 5, 2024
June Bray Director Jun 5, 2024
Rajiv Patni Director Jun 5, 2024

Recent Insider Transactions by Companies or Individuals for Quince Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.